Experience

Blueprint Medicines

• United States
• Biotechnology Research
• 400 - 500 Employee

• Associate Director of Translational Medicine

  • Jul 2022 - Present



Pyxis Oncology

• United States
• Biotechnology Research
• 1 - 100 Employee

• Principal Scientist of Translational Medicine

  • Dec 2021 - Jul 2022



Constellation Pharmaceuticals, A MorphoSys Company

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Senior Scientist

  • Feb 2021 - Dec 2021

  Translational lead of CPI-0209 program in prostate cancer and other solid tumors. •Identified and validated the biomarkers hypothesis for CPI-0209 in various indications. •Evaluated clinical biomarker assays from CROs to support clinical development. •Supported the recommended phase 2 dose (RP2D) for CPI-0209 by identifying the efficacious PK exposure in various pre-clinical animal models. •Established the first-in-human PK-PD relationship for EZH2 inhibitor in… Show more Translational lead of CPI-0209 program in prostate cancer and other solid tumors. •Identified and validated the biomarkers hypothesis for CPI-0209 in various indications. •Evaluated clinical biomarker assays from CROs to support clinical development. •Supported the recommended phase 2 dose (RP2D) for CPI-0209 by identifying the efficacious PK exposure in various pre-clinical animal models. •Established the first-in-human PK-PD relationship for EZH2 inhibitor in CPI-0209-01 phase 1 clinical trial using patient whole blood RNA-seq and plasma PK exposure. •Developed combination therapies strategy for CPI-0209 in various indications. A patent application was filed based on the in vivo and in vitro data generated in this study. •Generated strong in vivo preclinical data in both cell line derived xenograft and patient derived xenograft models to support the business development efforts in showing CPI-0209 has the potential to be the best-in-class EZH2 inhibitor. •Led pre-clinical and clinical NGS data and translational data analysis. •Identified and evaluated biomarker venders to support CDx development. •Drafted the translational section of clinical trial protocol, Development Safety Update Report (DSUR) and updated the investigator brochure (IB). •Interacted with multiple functions including clinical operation, biostatistician, clinical sample management, DMPK, and toxicology to facilitate the timely data sharing and analysis. •Supervised, trained, and mentored two research associates. Served as subject matter expert to other teams to support disease-related and translational-related requests.

• Scientist II

  • Apr 2019 - Jan 2021

  Translational lead of CPI-1205 program in prostate cancer and other solid tumors. •Originated, defined strategy, and implemented the biomarker reverse translational analysis for ProSTAR trial, a phase 1/2 clinical trial of CPI-1205 in prostate cancer, and identified biomarkers to enable patient enrichment strategy. A patent application was filed based on this analysis. •Completed PD analysis for CPI-1205-01 clinical trial in lymphoma and ORIOn-E clinical trial in combination… Show more Translational lead of CPI-1205 program in prostate cancer and other solid tumors. •Originated, defined strategy, and implemented the biomarker reverse translational analysis for ProSTAR trial, a phase 1/2 clinical trial of CPI-1205 in prostate cancer, and identified biomarkers to enable patient enrichment strategy. A patent application was filed based on this analysis. •Completed PD analysis for CPI-1205-01 clinical trial in lymphoma and ORIOn-E clinical trial in combination CPI-1205 with immune checkpoint inhibitors in various solid tumors to support clinical decisions.



Mayo Clinic

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Senior Research Fellow

  • Jan 2017 - Apr 2019

  Led projects of genomics and epigenetic mechanism and precision medicine in cancer. • Developed in-house technology platforms and bioinformatic pipelines to support genomics and epigenetics studies including targeted genome sequencing, ChIP-seq, ATAC-seq, RNA-seq, and RRBS. • Identified SNPs affecting chemotoxicity by targeted genome sequencing of patient samples. • Discovered c-MYC-induced enhancer dysregulation as a mechanism of targeted-therapy resistance by integrated analysis… Show more Led projects of genomics and epigenetic mechanism and precision medicine in cancer. • Developed in-house technology platforms and bioinformatic pipelines to support genomics and epigenetics studies including targeted genome sequencing, ChIP-seq, ATAC-seq, RNA-seq, and RRBS. • Identified SNPs affecting chemotoxicity by targeted genome sequencing of patient samples. • Discovered c-MYC-induced enhancer dysregulation as a mechanism of targeted-therapy resistance by integrated analysis of multi-OMICs. • Identified loss of HP1α expression as a biomarker for tumor metastatic potential by epigenomic profiling of cancer cell lines and clinical samples. • Established the role of a critical and novel enhancer as a biomarker in chemotherapy resistance in KRAS mutant tumors by in-depth study of the published ChIP-seq datasets. • Leaded collaborations with internal and external stakeholders including physicians, bioinformaticians, and scientists. • Established preclinical model of patient-derived colorectal tumor organoid. • Trained technicians and graduate students to apply CRISPR-based epigenome editing toolkit to manipulate histone/DNA modifications. • Supervised junior postdocs and graduate students conducting multiple research projects.

• Research Fellow

  • Sep 2012 - Jan 2017

  Conducted research on genetic and epigenetic regulation mechanism in cancer cells. •Optimized a shRNA screening assay to reduce the operation time from one week to a single day. And performed screenings using the improved platform to identify epigenetic regulators. •Generated and purified specific antibodies to support laboratory studies, which resulted in significantly improved result reproducibility and saved thousands of research fund. •Designed NGS experiments and applied… Show more Conducted research on genetic and epigenetic regulation mechanism in cancer cells. •Optimized a shRNA screening assay to reduce the operation time from one week to a single day. And performed screenings using the improved platform to identify epigenetic regulators. •Generated and purified specific antibodies to support laboratory studies, which resulted in significantly improved result reproducibility and saved thousands of research fund. •Designed NGS experiments and applied bioinformatics tools for data analysis and interpretation. •Translated results from bioinformatics pipeline (RNA-seq, ChIP-seq, etc.) into drug discovery screening strategies. •Supervised junior graduate and summer students in the lab.



The Hong Kong University of Science and Technology

• Hong Kong
• Higher Education
• 700 & Above Employee

• PhD candidate and Research Associate

  • Sep 2006 - Aug 2012

  Investigated the mechanism and cell cycle control of DNA replication. •Developed a high-throughput anti-cancer drug screening platform based on yeast-two-hybrid. •Characterized the protein-protein synthetic lethality interactions in the DNA replication machinery in budding yeasts and mammalian cells. •Investigated the regulation of DNA replication in normal and cancer cells. •Mentored 6 undergraduate students conducting their final year projects. Investigated the mechanism and cell cycle control of DNA replication. •Developed a high-throughput anti-cancer drug screening platform based on yeast-two-hybrid. •Characterized the protein-protein synthetic lethality interactions in the DNA replication machinery in budding yeasts and mammalian cells. •Investigated the regulation of DNA replication in normal and cancer cells. •Mentored 6 undergraduate students conducting their final year projects.